Human multidrug-resistant (MRP, p190) myeloid leukemia HL-60/ADR cells in vitro: Resistance to the mevalonate pathway inhibitor lovastatin

Neoplasma

Volumn 44, Issue 6, 1997, Pages 366-369

  Hunakova L ^a   Sedlak J ^a   Sulikova M ^a   Chovancova J ^a   Duraj, J ^a   Chorvath B ^a  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

Apoptosis; Cell cycle analysis; Cell line; Cytotoxicity; Human leukemia; Lovastatin; MDR 1; MRP; MTT test; Multidrug resistance

Indexed keywords

MEVALONIC ACID; MEVINOLIN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL DEATH; CELL STRAIN HL 60; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MULTIDRUG RESISTANCE; MYELOID LEUKEMIA;

EID: 0031404225     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. DIAMOND, A.M., JAFFE, D., MURRAY, J.L., SAFA, A.R., SAMUELS, B.L., HATFIELD, D.L.: Lovastatin effects on human breast carcinoma cells: Differential toxicity on an adriamycin-resistant derivative and influence on selenocysteine tRNAs. Biochem. Mol. Biol. Int., 38, 1996, 345-355.
2. DIMITROULAKOS, J., YEGER, H.: HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: Lovastatin significantly targets P-glycoprotein expressing cells. Nat. Med., 2, 1996, 326-333.
3. FLENS, M.J., IZQUIERDO, M.A., SCHEFFER, G.J., FRITZ, J.M., MEIJER, C.M., SCHEPER, R.J., ZAMAN, G.J.: Immunochemical detection of the multidrug-resistance-associated protein MRP in human multidrug resistant tumor cells by monoclonal antibodies. Cancer Res., 54, 1994, 4557-4562.
4. GRAYBABLIN, J., RAO, S., KEYOMARSI, K.: Lovastatin induction of cyclin-dependent kinase inhibitors in human breast cancer cells occurs in cell cycle-independent fashion. Cancer Res., 57, 1997, 604-609.
5. HOLMBERG, M., SANDBERG, C., NYGREN, P., LARSSON, R.: Effects of lovastatin on a human myeloma cell line: Increased sensitivity of a multidrug-resistant subline that expresses the 170 kDa P-glycoprotein. Anticancer Drugs, 5, 1994, 598-600.
6. IZQUIERDO, M.A., SCHEFFER, G.L., FLENS, M.J., SCHROIJERS, A.B., VAN DER VALK, P., SCHEPER, R.J.: Major vault protein LRP-related multidrug resistance. Eur. J. Cancer, 32A, 1996, 979-984.
7. IZQUIERDO, M.A., SCHEFFER, G.L., FLENS, M.J., SHOEMAKER, R.H., ROME, L.H.M., SCHEPER, R.J.: Relationship of LRP-human major vault protein to in vitro and clinical resistance to anticancer drugs. Cytotechnology, 19, 1996, 191-197.
8. KAVALLARIS, M.: The role of multidrug resistance-associated protein (MRP) expression in multidrug resistance. Anticancer Drugs, 8, 1997, 17-25.
9. KRISHNAMACHARY, N., CENTER, M.S.: The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190 kDa-membrane bound glycoprotein. Cancer Res., 53, 1993, 3658-3663.
10. LING, V.: The role of P-glycoprotein in drug resistance. In: Accomplishments in Cancer Research. Eds: Fortner, J.G., Rhoads, J.E. Philadelphia, J. B. Lippincott 1991, 282-291.
11. LING, V.: P-glycoprotein and resistance to anticancer drugs. In: Accomplishments in Cancer Research. Eds: Fortner, J.G., Rhoads, J.E. Philadelphia, J. B. Lippincott 1991, 78-89.
12. MARSH, W., SICHERI, D., CENTER, M.S.: Isolation and characterization of adriamycin-resistant HL-60 cells which are not defective in the initial accumulation of drug. Cancer Res., 46, 1996, 4053-4057.
13. METHERALL, J.E., Li, H., WAUGH, K.: Role of multidrug resistance P-glycoproteins in cholesterol biosynthesis. J. Biol. Chem., 271, 1996, 2634-2640.
14. MILLER, A.C., KARIKO, K., MYERS, C.E., CLARK, E.P., SAMID, D.: Increased radioresistance of EJ ras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21 ras isoprenylation. Int. J. Cancer, 53, 1993, 302-307.
15. MOSSMAN, T.: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assay. J. Immunol. Methods., 65, 1983, 55-63.
16. PIETSCH, A., ERL, W., LORENZ, R.L.: Lovastatin reduces expression of the combined adhesion and scavenger receptor CD36 in human monocyte cells. Biochem. Pharmacol., 52, 1996, 433-439.
17. PRASANNA, P., THIBAULT, A., LIU, J., SAMID, D.: Lipid metabolism as a target for brain cancer therapy: Synergistic activity of lovastatin and sodium phenylacetate against human glioma cells. J. Neurochem., 66, 1996, 710-716.
18. SCHEPER, R.J., BROXTERMAN, H.J., SCHEFFER, G.L., KAAUK, P., DALTON, W.D., VAN HEUNINGEN, T.H.M., VAN KALKEN, C.K., SLOVAK, M.L., DEVRIES, E.G.E., VANDERVALK, P., MEIJER, C.J., PINEDO, H.M.: Overexpression of a Mr 110 000 vesicular protein in non-P-glycoprotein mediated multidrug resistance. Cancer Res., 53, 1993, 1479-1485.
19. SEDLÁK, J., HUNÁKOVÁ, L., DURAJ, J., CHORVATH, B., NOVOTNÝ, L.: Effect of protein kinase inhibitor, staurosporine derivative CGP 41 251 on cell cycle, DNA synthesis and drug uptake in neoplastic cell lines. Anticancer Drugs, 6, 1995, 70-76.
20. SEDLÁK, J., HUNAKOVÁ, L., ŠULIKOVÁ, M., CHORVÁTH, B.: Protein kinase inhibitor-induced alterations of drug uptake, cell cycle and surface antigen expression in human multidrug resistant (Pgp and non-Pgp (MRP)) promyelocytic leukemia (HL-60) cells. Leukemia Res. In press.
21. WEBER, C., ERL, W., WEBER, P.C.: Lovastatin induces differentiation of Mono Mac 6 cells. Cell Biochem. Funct., 13, 1995, 273-277.
22. ZAMAN, G.J., FLENS, M.J., VAN LEUSDEN, M.R., DE HAAS, M., MULDER, H.S., LANKELMA, J., PINEDO, H.M., SCHEPER, R.J., BAAS, F., BROXTERMAN, H.J.: The human multidrug resistance associated protein MRP is a plasma membrane efflux pump. Proc. Natl. Acad. Sci. USA, 91, 1994, 8822-8825.